7210 Wareham Drive, Tampa, FL 33647
May 22, 2024 A majority of patients taking weight loss drugs discontinue use of their medication before reaching a clinically meaningful health benefit, according to new research published May 21 by the Blue Cross Blue Shield Association. The study was conducted by Blue Health Intelligence and is based on national pharmacy and medical claims data from […]
Most weight loss drug users quit before seeing benefits Read More »
May 9, 2024 Novo Nordisk is beginning work on a follow-up weight loss medicine that would last longer and could be manufactured more easily. On Thursday, the company unveiled a research project aimed at adding up to two more obesity treatments to its large pipeline, which already includes a long list of experimental obesity drugs
Novo Nordisk Working On Even Better Weight Loss Drugs Read More »
May 9, 2024 John LaRosa, Marketdata’s Research Director and founder, was recently interviewed by Kimberly Adams at Marketplace, a business and economic program, along with several others, about how the weight loss market is changing currently, being affected by the hugely popular GLP-1 weight loss medications. Here’s the interview, on audio. Click this link to
How GLP-1 Drugs Are Changing The Weight Loss Market – Podcast Read More »
May 2, 2024 Management reported that: “We delivered solid performance in the first quarter with end of period subscribers of 4.0 million, improved retention and engagement in our core business, and continued strong growth in our clinical business with 91 thousand end of period clinical subscribers,” said Sima Sistani, the Company’s CEO. “We continue to
Weight Watchers Reports Q1 Results Read More »
April 29, 2024 Management said that: “Our new model is highly differentiated from competitors, with a holistic approach including our habit-based and Coach guided solution along with nutrition products and community support. It will be supported by a reimagined framework for customer acquisition, with a new company-led national marketing campaign, enhancing both awareness of the
Medifast Reports Q1 2024 Results Read More »
April 29, 2024 According to an article at Biospace.com, GLP-1 agonists are set to become the best-selling drugs in 2024, but the biopharma industry isn’t resting on its collective laurels. Instead, some companies are pushing to improve upon the popular obesity medicines with therapies that promote higher-quality weight loss. Clinical studies have shown that up
Higher Quality Weight Loss Drugs Coming in the Future Read More »
March 4, 2024 U.S. Weight Loss Market Now Worth $90 Billion, Obesity Drug Sales Soar March 4, 2024 Marketdata LLC has just published a new analysis of the weight loss market: “The U.S. Weight Loss Market: 2024 Status Report & Forecast”, March 2024, 107 Pages Some findings: The total U.S. weight loss market is estimated
U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs Read More »
Feb. 28, 2024 WW reported its results for Q4 2023 and the full year today. WW reported results in line with analysts’ expectations in Q4 FY2023, with revenue down 8% year on year to $206 million. “2023 was a pivotal year as we began transforming our business for the future. We returned WeightWatchers to year
Weight Watchers Reports Q4 and 2023 Results Read More »
Feb. 20, 2024 Medifast reported full-year and Q4 results on February 20, 2023. 2023 revenues came in at $1.07 billion. The company employed 41,100 active earning Optavia health coaches, who had quarterly earnings of $4,648 (or $18,592 on an annual rate). Management said that: “We are realigning our business to respond to the evolving dynamics
Medifast Reports Q4 and Full Year 2023 Results Read More »
January 20, 2024 Novo Nordisk and Eli Lilly aren’t the only drug companies active in the prescription diet drugs space. Viking Therapeutics has a dual GLP-1/GIP agonist in Phase 2 clinical trials for treating obesity and liver fat reduction for injectable and oral administration. Rhythm Pharmaceuticals has an FDA-approved treatment for the treatment of MC4R-pathway-related
More Obesity Drugs In The Pipeline Read More »